|
Fibrosis
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
Genes involved in innate immunity associated with asbestos-related fibrotic changes.
|
24142982 |
2014 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
CTD_human |
Mangiferin significantly inhibited glomerular extracellular matrix expansion and accumulation and transforming growth factor-beta 1 overexpression in glomeruli of diabetic nephropathy rats.
|
19960420 |
2010 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
CTD_human |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
|
18682491 |
2009 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
|
19018797 |
2009 |
|
Kidney Failure, Chronic
|
0.600 |
Biomarker
|
disease |
CTD_human |
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
|
19420110 |
2009 |
|
Fibrosis
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress.
|
18705752 |
2008 |
|
Fibrosis
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
We show that local and transient TGF-beta1 overexpression induces homogenous, prolonged, and progressive pleural fibrosis without pleurodesis, associated with severe impairment of pulmonary function.
|
17947678 |
2007 |
|
Fibrosis
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium.
|
16306446 |
2006 |
|
Chronic Obstructive Airway Disease
|
0.600 |
Biomarker
|
disease |
CTD_human |
Abnormal expression of TGF-beta1 is believed to play an important role in the pathogenesis of a number of chronic inflammatory and immune lung diseases, including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.
|
16365456 |
2006 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
CTD_human |
Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction.
|
16310260 |
2006 |
|
Peritoneal Fibrosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Inhibition of TGF-beta1 expression in human peritoneal mesothelial cells (HPMC) may provide a potential treatment for PF.
|
17199790 |
2006 |
|
Osteoporosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
TGF-beta1 is commonly associated with a single base change resulting in a Leu(10)-->Pro (T(869)-->C) polymorphism and is a genetic marker for susceptibility to osteoporosis.
|
12706579 |
2003 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression.
|
11682445 |
2001 |
|
Lung diseases
|
0.600 |
Biomarker
|
group |
CTD_human |
Before these experiments, there was no information available that would provide a basis for predicting whether or not TGF-beta(1) expression induces fibroproliferative lung disease in fibrogenic-resistant TNF-alphaRKO mice, an increasingly popular animal model.
|
11472967 |
2001 |
|
Fibrosis
|
0.600 |
Biomarker
|
phenotype |
CTD_human |
In conclusion, this strongly suggests that TGF-beta1 derived from tubular epithelial cells and some macrophages might be related to the development of renal interstitial fibrosis in HgCl2-treated BN rats.
|
10469268 |
1999 |
|
Degenerative polyarthritis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Ten of the likely effector genes, including TGFB1 (transforming growth factor beta 1), FGF18 (fibroblast growth factor 18), CTSK (cathepsin K), and IL11 (interleukin 11), have therapeutics approved or in clinical trials, with mechanisms of action supportive of evaluation for efficacy in osteoarthritis.
|
30664745 |
2019 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues.
|
27605418 |
2016 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Role of NLRC5 in progression and reversal of hepatic fibrosis.
|
26806094 |
2016 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Therapeutic
|
disease |
CTD_human |
Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues.
|
27605418 |
2016 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Therapeutic
|
disease |
CTD_human |
Role of NLRC5 in progression and reversal of hepatic fibrosis.
|
26806094 |
2016 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk.
|
24836286 |
2014 |
|
Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice.
|
23090186 |
2013 |
|
Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Protective effect of Gui Qi mixture on the progression of diabetic nephropathy in rats.
|
17177138 |
2006 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Therapeutic
|
disease |
CTD_human |
The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis.
|
16579972 |
2006 |
|
Liver Cirrhosis, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis.
|
16579972 |
2006 |